Trial Profile
The effects of salmeterol/fluticasone on circulating biomarker in stable chronic obstructive pulmonary disease.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 May 2012
Price :
$35
*
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary) ; Ipratropium-bromide/salbutamol
- Indications Chronic obstructive pulmonary disease
- Focus Biomarker; Pharmacodynamics
- 17 Jul 2009 New trial record.